|
Published by: PJB Publications USA Inc.
Published: Jul. 1, 2003 - 142 Pages
Table of Contents
1 Executive Summary
1.1 Scope and Objectives of the Report
1.2 Methodology
1.2.1 Determining Disease Prevalence
1.2.2 Sales and CAGR Estimates and Projections
1.2.3 Company Profiles
1.3 Market Overview
1.3.1 Drug Products and Competitors
1.3.2 Positive Market Factors
1.3.3 Negative Market Factors
1.4 Disease Management Considerations
2 Overview of Anemia
2.1 Description and Def
2.2 Prevalence
2.3 Pathophysiology
2.3.1 Deficient Erythropoiesis
2.3.2 Blood Loss
2.3.3 Hemolysis (Red Blood Cell Depletion)
2.4 Diagnostic Testing
2.4.1 Complete Blood Count (CBC)
2.4.2 Red Blood Cell Count and Indices
2.4.3 Hemoglobin and Hematocrit
2.4.4 Reticulocyte Count
2.4.5 Iron Status
2.5 Grading Anemia Severity
3 Types of Anemia
3.1 Iron Deficiency A
3.1.1 Description
3.1.2 Prevalence
3.1.3 Risk Factors
3.1.4 Signs and Symptoms
3.1.5 Diagnosis
3.1.6 Treatment
3.2 Vitamin B12 Deficiency Anemia
Abstract Anemia is an increasingly prevalent disorder and is becoming a major public health concern due to the silent nature of the condition.
This report is designed to present clinical and market positioning data on anemia treatments and management, with special emphasis on anemia associated with chronic disease.
This market research study is comprehensive in scope and covers key topics of interest to pharmaceutical and biotechnology companies.
Diseases associated with anemia discussed in this report are:
· Chronic kidney disease
· Cancer
· HIV/AIDS
· Hepatitis
· Autoimmune diseases
· Cardiovascular disease
An essential strategic resource, Theta’s Anemia Management: World Drug Markets provides the answers to these vital questions:
· What is the economic impact on the treatment of persons suffering anemia of chronic disease?
· What are the preventitive health issues as relates to provider treatment variances?
· What is the current US and worldwide market for anemia of chronic disease treatments? What are the market predictions for 2002-2006?
· Who are the key manufacturers that provide drugs to prevent & treat anemia of chronic disease? Who are their biotechnology partners?
· What future drug research is underway in the field of genomics and what other novel approaches are being investigated?
· What are the Disease Management implications for health organizations who provide drugs to this market segment?
Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Get Full Details About This Report >>
|
